Bradley McGregor, MD


Activity Observed With Cabozantinib/Nivolumab/Ipilimumab in RCCvh

In an interview with Targeted Oncology, Bradley A. McGregor, MD, discussed the main takeaways from a phase 3 study of cabozantinib, nivolumab, and ipilimumab for patients with renal cell carcinoma with variant histologies.

Bradley Monk, MD


OUTBACK Trial Reveals No Benefit for Adjuvant Chemotherapy in Cervical Cancer

Bradley Monk, MD, FACCOG, FACS, discusses the creation and findings of the OUTBACK trial.

Bradley Prechtl, MBA


Improving Community Oncology Practices Through the American Oncology Network

The American Oncology Network is helping community oncology practices to flourish. As CEO, Bradley Prechtl, MBA, was instrumental in the organizations formation in 2017 when the need for improvement in community oncology across the United States had become evident.

Brandon Scalea


Ibrutinib Maintenance Appears Safe in MCL Following Induction Therapy

Ibrutinib as a maintenance therapy for patients with mantle cell lymphoma who respond to frontline induction therapy with or without autologous stem cell transplant appeared safe and feasible, according to the results of a recent study presented at the 2019 ASCO Annual Meeting.

Brennan J. Decker, MD, PhD


Identification of EGFR Mutations Impacts Overall Prognosis in Lung Cancers

Brennan J. Decker, MD, PhD, discusses the role of identifying&nbsp;<em>EGFR</em>&nbsp;mutations in patients with lung cancers. In lung adenocarcinoma, there are many different activating mutations that can lead to the development of cancer, Decker explains.

Brian A. Van Tine, MD, PhD


Understanding Molecular Subtypes of Sarcoma

Brian A. Van Tine, MD, PhD, assistant professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine, discusses the importance of understanding molecular subtypes of sarcoma.

Brian Burgess, DO, PhD


Challenges With Targeted Therapies in Ovarian Cancer

Brian Burgess, DO, PhD, a first-year fellow at the University of Kentucky, discusses the biggest challenge with targeted therapies in ovarian cancer. PARP resistance has become a huge barrier in this treatment paradigm.&nbsp;

Brian G.M. Durie, MD


Revlimid Plus Dexamethasone Versus Standard Treatment for Multiple Myeloma

Brian G.M. Durie, MD, chairman, International Myeloma Foundation (IMF), hematologist/oncologist, Cedars-Sinai Medical Center, Los Angeles, California, discusses results from a phase III trial that compared lenalidomide (Revlimid) plus dexamethasone versus the standard treatment of melphalan plus prednisone and thalidomide (MPT) in patients with multiple myeloma who are over 65 years old. Durie offers his thoughts regarding the impact of this trial.

Brian Hoyle, PhD


Prevention of Cytomegalovirus After Allogeneic HSCT

Two poster presentations at the 2018 BMT Tandem Meetings of the Center for International Blood &amp; Marrow Transplant Research and the American Society for Blood and Marrow Transplantation, provided a compelling&nbsp;extension of the recent phase III clinical trial that demonstrated the efficacy of prophylactic therapy with letermovir (Prevymis) for the prevention of cytomeg&nbsp;alovirus (CMV) infection in patients receiving allogeneic hematopoietic stem cell transplantation (HSCT).

Brian I. Rini, MD


First-Line Treatment for Advanced Clear Cell RCC: Key Takeaways

Closing out their discussion on advanced RCC, expert hematologist/oncologists offer key takeaways from their discussion and look toward future treatment evolution in the first-line setting.

Brian Leyland-Jones, MBBS, PhD


Results of the SWOG S0500 Trial

Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, discusses the results of the SWOG S0500 trial, which looked at circulating tumor cell (CTC) levels in patients with metastatic breast cancer.

Brian Nussenbaum, MD, FACS


Dr. Brian Nussenbaum on the Difficulties of Improving Survival in Larynx Cancer

Nussenbaum says the current balance in the treatment paradigm of larynx cancer is between surreal and cure, all while maintaining a functional preservation for the patient.

Brian Rini, MD


Unmet Needs and Future Outlook in aRCC Treatment

The panel explores unmet needs in aRCC treatment and shares expectations for changes and advances in the landscape in the near future.

Brian T. Hill, MD, PhD


Evolving Role of CAR T-Cell Therapy in Mantle Cell Lymphoma

Brian Hill, MD, discusses the use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma and identifies other novel agents in this setting.

Brian Van Tine, MD, PhD


Dr. Van Tine Discusses the Development of Olaratumab in Sarcoma

Brian Van Tine, MD, PhD, assistant professor, Washington University School of Medicine, discusses the development of olaratumab (Lartruvo) in soft tissue sarcoma.

Bridget F. Koontz, MD


Results of a Phase II Study of LHRH Therapy in High-Risk Prostate Cancer

Bridget F. Koontz, MD, associate professor of radiation oncology, Duke Cancer Institute, discusses a single-arm, phase II trial of 6 months of concurrent androgen deprivation therapy/abiraterone acetate (Zytiga) plus prednisone and definitive radiotherapy for men with intermediate- to high-risk localized prostate cancer.

Bridget M. Kuehn


Genomic Profiling Provides Much-Needed Prognostic Data in Glioma

Results from a genomic and molecular analysis presented at the 2015 ASCO Annual Meeting and published in Acta Neuropathology indicate that low-grade gliomas may be classified into three distinct prognostic categories based on genomic data.

Brielle Benyon


Acalabrutinib Shows No New Safety Signals in Treating Older, Frail Patients With CLL

Older with chronic lymphocytic leukemia patients been underrepresented in clinical trials. The phase 2 CLL-FRAIL trial focuses on this population.

Brielle Urciuoli


Expert Discusses Long-Term Efficacy of Pembrolizumab in Melanoma

Eric Whitman, MD, discusses data for pembrolizumab in the frontline treatment of advanced melanoma and ongoing research with the agent in other settings of the disease.

Brigid Stadinski, PhD


Novel Treatment Strategies Are Explored in Pancreatic Cancer

Outcomes in pancreatic cancer may be improving for the first time in decades. With pancreatic cancer projected to be the second leading cause of cancer-related deaths in the United States by the year 2030,1 this projection brings welcome optimism to the field.

Brittany Lovely


Early Activity With Frontline Sacituzumab Govitecan/Pembro in Metastatic NSCLC

In patients with metastatic non–small cell lung cancer given sacituzumab govitecan-hziy with pembrolizumab, positive response rates were observed.

Brittany N. Bohinc, MD


Using the LGR5 Protein as a Biomarker in Thyroid Cancer

Brittany N. Bohinc, MD, Division of Endocrinology, Duke University, discusses the potential to use LGR5 as a biomarker in papillary thyroid cancer.

Brock O'Neil, MD


Dr. O'Neil Discusses Robotic Prostatectomy Versus Open Surgery

Brock O'Neil, MD, physician instructor in urologic surgery, Vanderbilt University, discusses robotic prostatectomy versus open surgery.

Bruce D. Cheson, MD


The Mechanism of Action and Use of Antibody Drug Conjugates

Bruce D. Cheson, MD, Professor of Medicine, Head of Hematology, Director of Hematology Research, Georgetown Lombardi Comprehensive Cancer Center, describes the mechanism of action of antibody drug conjugates and their use.

Bruno Daniele, MD


The Significance of the RESORCE Trial in HCC

Bruno Daniele, MD, director, Department of Oncology and Medical Oncology, G. Rummo Hospital, Italy, discusses the significance of the RESORCE trial, which examined the use of regorafenib (Stivarga) as a treatment for patients with hepatocellular carcinoma (HCC).

Bryan D. Choi, MD, PhD


Engineering Chimeric Antigen Receptor T Cells to Treat Glioblastoma

The authors share their experience with EGFRvIII-specific chimeric antigen receptors, which they hope will contribute to the growing body of research committed to discovering a novel therapy for glioblastoma.

By Jennifer Shepphird, PhD


Anti-Androgen Not for Male Cancers Alone

A potential pathogenic role for the androgen receptor (AR) exists for some breast cancer (BC) subtypes according to 2 new studies presented at the San Antonio Breast Cancer Symposium (SABCS) 2014.

By Peter J. Sciavolino, PhD


Tropomyosin-Related Kinases (TRK) Making Headway in Head and Neck Cancer

Treatment of certain head and neck cancers may soon be fundamentally transformed through the use of molecular diagnostics to dissect essential oncogenic driver pathways, and ultimately to identify targeted therapies that specifically inhibit them.